Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−47 JPY
−3.61 B JPY
6.12 B JPY
28.41 M
About TAIKO PHARMACEUTICAL CO LTD
Sector
Headquarters
Osaka
Founded
1940
Website
ISIN
JP3442200006
FIGI
BBG000DPW4Z7
Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs. It operates through the following segments: Pharmaceuticals, Infection Control, and Others. The Pharmaceuticals segment handles the sale of gastrointestinal drugs such as Seirogan, Seirogan Toui A, and Seirogan Quick C. The Infection Control segment offers hygiene products such as Cleverin and clev&and. The Others segment provides vinegar-related products. The company was founded by Otojiro Shibata in July 1940 and is headquartered in Osaka, Japan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4574 is 317 JPY — it has decreased by −0.94% in the past 24 hours. Watch TAIKO PHARMACEUTICAL CO LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange TAIKO PHARMACEUTICAL CO LTD stocks are traded under the ticker 4574.
4574 stock has fallen by −3.35% compared to the previous week, the month change is a −12.43% fall, over the last year TAIKO PHARMACEUTICAL CO LTD has showed a 12.81% increase.
4574 reached its all-time high on Aug 20, 2020 with the price of 2,928 JPY, and its all-time low was 197 JPY and was reached on May 31, 2012. View more price dynamics on 4574 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4574 stock is 3.15% volatile and has beta coefficient of 0.85. Track TAIKO PHARMACEUTICAL CO LTD stock price on the chart and check out the list of the most volatile stocks — is TAIKO PHARMACEUTICAL CO LTD there?
Today TAIKO PHARMACEUTICAL CO LTD has the market capitalization of 15.91 B, it has decreased by −0.91% over the last week.
Yes, you can track TAIKO PHARMACEUTICAL CO LTD financials in yearly and quarterly reports right on TradingView.
TAIKO PHARMACEUTICAL CO LTD is going to release the next earnings report on May 20, 2025. Keep track of upcoming events with our Earnings Calendar.
4574 net income for the last quarter is −50.00 M JPY, while the quarter before that showed 292.00 M JPY of net income which accounts for −117.12% change. Track more TAIKO PHARMACEUTICAL CO LTD financial stats to get the full picture.
As of Dec 21, 2024, the company has 208.00 employees. See our rating of the largest employees — is TAIKO PHARMACEUTICAL CO LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TAIKO PHARMACEUTICAL CO LTD EBITDA is 532.00 M JPY, and current EBITDA margin is −4.93%. See more stats in TAIKO PHARMACEUTICAL CO LTD financial statements.
Like other stocks, 4574 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TAIKO PHARMACEUTICAL CO LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TAIKO PHARMACEUTICAL CO LTD technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TAIKO PHARMACEUTICAL CO LTD stock shows the strong sell signal. See more of TAIKO PHARMACEUTICAL CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.